ACTIN Report

PATIENT
ACTN01029999

REPORT DATE
05-Oct-2022

Gender: Male | Birth year: 1950 | WHO: 1

Tumor: Skin - Melanoma | Lesions: CNS, Liver, Lymph nodes | Stage: IV

Summary

Patient clinical history (25-Sep-2022)

Relevant systemic treatment history	**Vemurafenib (10/2021), Ipilimumab (2022)**
Other oncological history	**Resection (2020)**
	Previous primary tumor: Lung carcinoma (diagnosed 10/2019, considered non-active)
Relevant non-oncological history	**Pancreatitis**

Molecular results

Previous relevant molecular results	**BRAF V600E positive (BRAF test)**

WGS molecular results (30-Sep-2022)

Biopsy location	**Liver**
Events with approved treatment evidence in General	**None**
Events with trial eligibility in Local database	**PTEN del**
Additional events with trial eligibility in NL (External)	**High TML**
Additional events with experimental evidence (General)	**High TML**
Additional events with off-label experimental evidence in General	**BRAF V600E**

Approved treatments considered eligible

Treatment
Not yet determined

Local trials that are open and considered eligible (2)

Trial	Acronym	Cohort	Molecular	Warnings
Test Trial 1	TEST-1	Cohort B	PTEN del	Undetermined SOC exhaustion
Test Trial 2 *	TEST-2	Cohort A	None	None

* Cohort currently has no slots available

External trials potentially eligible based on molecular results

Event	Trials
High TML	External test trial 2
PTEN del	External test trial 1

Molecular Details (WGS performed on ACTN01029999T)

General

Purity	Sufficient Quality	Predicted tumor origin	TML Status	TMB Status	MS Stability	HR Status	DPYD
98%	Yes	Melanoma (100%)	**High (185)**	**High (13.7)**	Stable	Proficient	1* HOM (Normal function)

Drivers

Type	Driver	Driver likelihood	Trials in Local	Trials in External	Best evidence in General	Resistance in General
Mutation (Hotspot)	BRAF p.V600E (4/6 copies)	High			Experimental	
Loss	PTEN del	High	TEST-1	External test trial 1		

ACTIN Report

PATIENT
ACTN01029999

REPORT DATE
05-Oct-2022

Clinical Details

Patient current details (25-Sep-2022)

Unresolved toxicities grade => 2	**Fatigue (2)**
Cancer-related complications	**Ascites**
Known allergies	**Wasps (Environment)**
Recent surgeries	**05-Sep-2022**

Tumor details (25-Sep-2022)

Measurable disease	**Yes**
CNS lesion status	**Present CNS lesions (active)**
Brain lesion status	**No known brain lesions**

Laboratory results

			25-Sep-2022	15-Sep-2022	05-Sep-2022
Liver function	Total bilirubin				
	ASAT	(< 33 U/L)	36 U/L		
	ALAT				
	ALP				
	Albumin				
Kidney function	Creatinine				
	CKD-EPI eGFR	(> 100 mL/min)			**> 100 mL/min**
Other	Hemoglobin	(6.5 - 9.5 mmol/L)	5.5 mmol/L		
	Thrombocytes	(155 - 350 10^9/L)	150 10^9/L	151 10^9/L	**155 10^9/L**
	LDH	(< 245 U/L)		**240 U/L**	
Tumor markers	CA 15.3				
	CA 125				
	CA 19.9				
	CEA				
	PSA				

Medication details

Medication	Categories	Start date	Stop date	Status	Dosage	Frequency
Ibuprofen	NSAIDs	05-Sep-2022	20-Oct-2022	Active	750 - 1000 mg	1 / day

Blood transfusions

Product	Date
Thrombocyte concentrate	20-Sep-2022

Trial Matching Summary

Local trials that are closed or blacklisted but considered eligible (0)

Trial	Acronym	Cohort	Molecular	Warnings
None				

Local trials not considered eligible (3)

Trial	Acronym	Cohort	Open	Ineligibility reasons
Test Trial 1 *	TEST-1	Cohort A	Yes	Active CNS metastases
Test Trial 1	TEST-1	Cohort C	No	Active CNS metastases
Test Trial 2	TEST-2	Cohort B	Yes	Vemurafenib treatment

* Cohort currently has no slots available

Trial Matching Details

Potentially eligible open trials & cohorts

Test Trial 1

Potentially eligible	**Yes**
Acronym	**TEST-1**
Title	**Example test trial 1**

Rule	Reference	Evaluation
I-02	This rule has 2 conditions: 1. Patient has no active brain metastases. 2. Patient has exhausted SOC.	UNDETERMINED Could not be determined if patient has exhausted SOC
I-01	Patient must be an adult	PASS Patient is at least 18 years old
I-02	This rule has 2 conditions: 1. Patient has no active brain metastases 2. Patient has exhausted SOC	PASS Patient has no known brain metastases

Test Trial 1 - Cohort A

Cohort ID	**A**
Potentially eligible?	**No**
Open for inclusion?	**Yes**
Has slots available?	**No**

Rule	Reference	Evaluation
E-01	Active CNS metastases	FAIL Patient has active CNS metastases

Test Trial 1 - Cohort B

Cohort ID	**B**
Potentially eligible?	**Yes**
Open for inclusion?	**Yes**
Has slots available?	**Yes**

Test Trial 1 - Cohort C

Cohort ID	**C**
Potentially eligible?	**No**
Open for inclusion?	**No**
Has slots available?	**No**

Rule	Reference	Evaluation
E-01	Active CNS metastases	FAIL Patient has active CNS metastases

ACTIN Report

PATIENT
ACTN01029999

REPORT DATE
05-Oct-2022

Test Trial 2

Potentially eligible	**Yes**
Acronym	**TEST-2**
Title	**Example test trial 2**

Rule	Reference	Evaluation
I-01	Patient should have measurable disease	PASS Patient has measurable disease
I-02	Patient should be able to give adequate informed consent	NOT_EVALUATED It is assumed that patient can provide adequate informed consent

Test Trial 2 - Cohort A

Cohort ID	**A**
Potentially eligible?	**Yes**
Open for inclusion?	**Yes**
Has slots available?	**No**

Test Trial 2 - Cohort B

Cohort ID	**B**
Potentially eligible?	**No**
Open for inclusion?	**Yes**
Has slots available?	**Yes**

Rule	Reference	Evaluation
I-03	Patient should not have had Vemurafenib treatment	FAIL Patient has had Vemurafenib treatment